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Abstract
Three recent sets of null findings from trials of alcohol brief intervention (BI) have been disappointing to those who
wish to see a reduction in alcohol-related harm through the widespread dissemination of BI. Saitz (7) has suggested
that these null findings result from a failure to translate the effects of BI seen in efficacy trials, which are thought to
contribute mainly to the beneficial effects of BI shown in meta-analyses, to effectiveness trials conducted in real-world
clinical practice. The present article aims to: (i) clarify the meaning of the terms “efficacy” and “effectiveness” and other
related concepts; (ii) review the method and findings on efficacy-effectiveness measurement in the 2007 Cochrane
Review by Kaner and colleagues; and (iii) make suggestions for further research in this area. Conclusions are: 1) to avoid
further confusion, terms such as “efficacy trial”, “effectiveness trial”, “clinical representativeness”, etc. should be
clearly defined and carefully used; 2) applications of BI to novel settings should begin with foundational research
and developmental studies, followed by efficacy trials, and political pressures for quick results from premature
effectiveness trials should be resisted; 3) clear criteria are available in the literature to guide progress from efficacy
research, through effectiveness research, to dissemination in practice; 4) to properly interpret null findings from
effectiveness studies, it is necessary to ensure that interventions are delivered as intended; 5) in future meta-analyses of
alcohol BI trials, more attention should be paid to the development and application of a psychometrically robust scale
to measure efficacy-effectiveness or clinical representativeness; 6) the null findings under consideration cannot be firmly
attributed to a failure to translate effects from efficacy trials to real-world practice, because it is possible that the majority
of trials included in meta-analyses on which the evidence for the beneficial effects of alcohol BI was based tended to
be effectiveness rather than efficacy trials; and 7) a hypothesis to explain the null findings in question is that they are
due to lack of fidelity in the implementation of BI in large, organizationally complex, cluster randomized trials.
Keywords: Alcohol-related harm, Brief interventions, Efficacy trials, Effectiveness trials, Meta-analyses
Introduction
There recently have been three disappointing sets of findings
from randomized controlled trials (RCTs) of alcohol brief
intervention (BI) in primary care. From the standpoint of
science, no findings are disappointing if they are an accurate
reflection of reality; however, because these are all null find-
ings, they are considered disappointing to those who wish to
see a substantial reduction in alcohol-related harm through
the widespread delivery of BI in routine practice. The fact
that all three trials were located in primary health care,
long considered the most promising setting for the deliv-
ery of alcohol BI [1], adds to this sense of disappointment.
In chronological order, the first findings were from a
cluster RCT of a tailored, multifaceted improvement
program in facilitating the implementation of BI by
general medical practitioners (GPs) in The Netherlands
(van Beurden et al.) [2]. The improvement program
consisted of a range of activities aimed at GPs, their or-
ganizations, and their patients. It took advantage of best
evidence on how best to encourage GPs to deliver BI
and the extensive experience of several of the investiga-
tors in this area. It represented, in short, the best chance
for success in encouraging GPs to become involved in
the delivery of alcohol BI. Unfortunately, the authors
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concluded that their program “failed to show an effect
and proved difficult to implement” (p. 1601) and that,
“there remains little evidence to support the use of such
an intensive implementation program to improve the
management of harmful and hazardous alcohol con-
sumption in primary care” (p. 1601).
The second set of findings came also from a cluster
RCT of a training program for GPs in Wales [3], but the
training in this case was for the delivery of brief behavior
change counseling for multiple lifestyle behaviors (smok-
ing, lack of exercise, unhealthy eating, and excessive alco-
hol consumption), so the main outcome measure was
changes in patient rather than GP behavior. The BI train-
ing program, known as PRE-EMPT, was based on motiv-
ational interviewing [4] and its effects were compared with
delayed training. Three months after a BI, there were no
differences between groups in the proportion of patients
reporting beneficial changes in at least one of the four risky
behaviors, including excessive drinking. The conclusion
was that training GPs in behavior change counseling had
no effect on patient self-reported behavior change.
The third null findings came from the primary care
arm of the SIPS (Screening and Intervention Programme
for Sensible Drinking) project [5], a cluster RCT in England
involving three conditions: (i) a control group given a
patient information leaflet (PIL); (ii) a group given the
PIL plus 5 minutes of structured brief advice, and (iii) a
group given the PIL, brief advice, and 20 minutes of
brief lifestyle counseling. At both 6- and 12-month
follow-up, there were no differences between groups in
the proportion of patients who had reduced their score
on the Alcohol Use Disorders Identification Test (AUDIT)
[6] from above to below the recommended cut point; i.e.,
indicating a beneficial change. The authors’ conclusion
was that “… evidence that brief advice or brief lifestyle
counseling provided additional benefit in reducing hazard-
ous or harmful drinking compared with the patient infor-
mation leaflet was lacking” (p. 2).
It is important to note that, given the large sample
sizes in all three studies discussed here, lack of statistical
power is unlikely to be the reason for null findings.
An exchange of views
Because of their relevance to present concerns, com-
ments by Richard Saitz on the SIPS findings [7] are
worth quoting at length:
“Particularly given the robust findings from systematic
reviews that favor brief intervention … when
compared to no brief intervention in efficacy trials …,
the conclusion most consistent with these data is that,
even when great efforts are made to implement SBI
(screening and brief intervention) in real-world
clinical care (e.g., with less external researcher
support), the effects seen in efficacy studies do not
translate into effective interventions in practice.”
Saitz continues:
“And the effect sizes in efficacy studies, while large
from a public health perspective, are small enough
(e.g., three fewer drinks per week) that they could
easily be erased when SBI is not implemented in
practice exactly like it was in those studies….Yet
alcohol SBI can only reach its potential if the effects
seen in efficacy studies can be achieved in real-world
practice. Kaner et al.’s [8] systematic review suggested
that the practice was similarly effective in trials in
which SBI implementation looked more like it would
in clinical practice and less like research
implementation, but none of those studies came close
to being pragmatic trials like SIPS, so they couldn’t
really inform that question.” (citation added)
Saitz observed that the SIPS trial was one of the few
pragmatic implementation studies of alcohol SBI and
that another trial, the van Beurden et al. trial [2] men-
tioned above, had an even more disappointing result. The
overall conclusion was that “… researchers and educators
should turn their attention to how to implement alcohol
screening and brief intervention in clinical practice in a
way that retains the efficacy seen in clinical trials.” Saitz
here has put his finger on the most pressing challenge fa-
cing the alcohol BI field at the present time, a challenge
that concerns the crucial distinction between efficacy and
effectiveness research.
In their reply to Saitz, the SIPS investigators [9] wrote
as follows:
“In contrast to Professor Saitz, we feel that the brief
intervention evidence base to date has indicated … a
growing preponderance of effectiveness rather than
efficacy trials. (In the Cochrane Review) … the
majority of studies … were judged to be clinically
relevant effectiveness trials (with high external
validity) rather than ideal-world efficacy trials (with
high internal validity). In a field that has evolved for
over 25 years, it is to be expected that evaluations
have increasingly reflected the variability and
constraints of real-world primary care.”
Kaner and colleagues also pointed to the difference be-
tween the SIPS trial, in which the aim was to evaluate
the impact of SBI on patients’ drinking outcomes, and
the van Beurden trial, which was a service-delivery trial
to evaluate the impact of an intensive, multifaceted im-
provement program on GPs’ management of alcohol
problems.
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Aims of this article
In this exchange of views, then, there appears to be dis-
agreement and possibly some confusion over the meaning
and applicability of the terms “efficacy”, “effectiveness”,
“implementation, and “pragmatic” trials. There are also
different views on whether the studies included in the
Kaner et al. Cochrane Review [8] were primarily efficacy
or effectiveness trials. With these issues in mind, the
present article has three aims:
I. To clarify the meaning of the terms efficacy trial,
effectiveness trial, and other related concepts, and to
try to dispel some of the confusion surrounding
these terms;
II. To review the method and findings on efficacy-
effectiveness measurement in the Kaner et al.
Cochrane Review [8];
III.To make suggestions for further research concerning
the efficacy-effectiveness distinction.
Explanatory versus pragmatic trials
In the current literature on alcohol BI, the terms
“effectiveness trial” and “pragmatic trial” seem to be
used synonymously. It is, of course, perfectly legitimate
to use the word “pragmatic” in its ordinary language
sense and, in this way perhaps, as the same in meaning
to “effectiveness.” (The meaning of effectiveness trial
will be considered below). However, the term prag-
matic trial does have a more technical meaning deriv-
ing from a paper in the early literature by two French
authors [10].
In this usage, explanatory trials are primarily concerned
with understanding, whereas pragmatic trials are con-
cerned primarily with decision. Thus, in a pragmatic trial,
treatments are compared “under the conditions in which
they would be applied in practice” (p. 638). A recent ex-
ample is the United Kingdom Alcohol Treatment Trial
(UKATT) [11] in which the intensity and therapeutic
methods of the two forms of treatment being compared
were deliberately confounded in the design (eight sessions
of Social Behavior and Network Therapy versus three
sessions of Motivational Enhancement Therapy, both
over 12 weeks). This was because the aim of the trial
was to determine which of two treatments was the more
effective and/or cost-effective in the form in which it
was intended to be delivered and in order to inform a
decision as to which should be rolled out in routine
practice in the UK National Health Service. If this had
been an explanatory trial, it would have been necessary
to control for either intensity or treatment type so that
the effect of the other on outcomes could be independ-
ently assessed; but this was not necessary in a pragmatic
trial. The explanatory-pragmatic distinction is clearly
similar in some ways to efficacy-effectiveness, but it has
special implications for the aims and design of a trial.
The seminal work of Brian Flay
Flay [12] published his seminal paper on the efficacy-
effectiveness distinction in 1986, certainly the first in the
area of substance use disorders and possibly in public
health in general. Flay credits Cochrane [13] in 1971
with first making the distinction in question, though the
potential for confusion here is illustrated by the fact that
Cochrane used “effectiveness” and “efficiency” for Flay’s
“efficacy” and “effectiveness.” Flay’s paper is concerned
with health promotion and is illustrated by examples
from smoking prevention, but it is highly relevant to re-
search on alcohol BI.
Flay first provides general definitions:
 Efficacy trials provide tests of whether a technology,
treatment, procedure, or program does more good
than harm when delivered under optimum
conditions.
 Effectiveness trials provide tests of whether a
technology, treatment, procedure, or program does
more good than harm when delivered under real-
world conditions.
Note immediately that efficacy is necessary to but not
sufficient for effectiveness (i.e., if a treatment is effective,
it must be efficacious but, if it is efficacious, it need not
necessarily be effective). Thus, if an effectiveness trial
produces a null result, one cannot be sure without a pre-
ceding efficacy trial whether the null result is due to lack
of efficacy or lack of effectiveness.
In somewhat more detail, an efficacy trial provides a
test of (i) a well-specified standardized treatment/pro-
gram that (ii) is made available in uniform fashion,
within standardized contexts/setting, to a specified target
group, which (iii) completely accepts, participates in, com-
plies with, or adheres to the treatment/program as deliv-
ered. However, an intervention in a real-world setting will
be effective only if an efficacious intervention is delivered/
implemented in such a way as to be made available to an
appropriate target clientele in a manner acceptable to
them (i.e., that they will be receptive to, participate in,
comply with, or adhere to). Thus, the observed effects, or
lack thereof, of an intervention in an effectiveness trial
may be due to one or more of the following: (i) the efficacy
level of the evaluated intervention; (ii) the availability of
the intervention to the target population; or (iii) the level
of acceptance of (participation in, compliance with, or
adherence to) the intervention by the target group.
However, there are two types of effectiveness trials:
treatment effectiveness trials and implementation effective-
ness trials. Relationships between three types of research –
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efficacy trials and the two types of effectiveness trials – are
shown in Table 1, which illustrates the role of the two key
variables, availability and acceptance, underlying the dis-
tinctions between them. An efficacy trial optimizes both
availability and acceptance; a treatment effectiveness trial
optimizes availability and leaves acceptability to vary; and
an implementation effectiveness trial leaves both to vary.
A key difference between treatment and implementa-
tion effectiveness trials is that the main outcome variable
in the former refers to some aspect of patient/client be-
havior, whereas the main outcome in the latter concerns
the behavior of the practitioners who deliver the inter-
ventions. From this point of view, it is clear that SIPS [5]
was a treatment effectiveness trial and the van Beurden
et al. trial [2] was an implementation effectiveness study.
Though the PRE-EMPT trial [3] was an examination of
the effects of training, the implementation of the inter-
vention was controlled and it was the acceptability of
the intervention to clients that was left to vary. So, with
the main outcome being changes in patient behavior at
follow-up, this was a treatment effectiveness trial. In re-
lation to the van Beurden trial [2] it seems that the null
findings were due to the failure of the improvement pro-
gram to motivate enough GPs to deliver BI, not to the
failure of the intervention itself to affect patients’ behav-
ior. It is therefore not relevant to the main issue under
discussion – the comparison of effects between efficacy
and treatment effectiveness trials.
For present purposes, the main thing missing from
Flay’s discussion is a consideration of intervention fidel-
ity; i.e., the extent to which the intervention is delivered
as intended and as shown to have been efficacious in
previous research. In Flay’s logic, it is simply assumed
that, in both kinds of effectiveness trials, the intervention
has been implemented as intended. So, the main difficulty
in mounting a true effectiveness study in Flay’s terms is of
ensuring that the intervention was delivered faithfully in
its efficacious form. The gap between a BI protocol and its
delivery in general practice has been described in the lit-
erature [14] and was first noted as a problem in the con-
duct of the earliest trial of alcohol BI in primary care [15].
Implementation fidelity is especially likely to be an issue in
large, organizationally-complex, cluster randomized trials
like SIPS [5] and PRE-EMPT [3].
Phases of research in the development of preventive
interventions
Based on his analysis of the efficacy-effectiveness distinc-
tion and experience with research on smoking cessation,
Flay [12] proposed eight phases of research that should
underlie the development of health promotion programs.
Rather than show this particular sequence of phases of re-
search, Table 2 shows a somewhat simpler sequence de-
rived from Flay’s later collaboration with Harold Holder
and colleagues on phases of alcohol problem prevention
research [16]. In phase IV of this sequence, the distinction
between treatment effectiveness trials and implementation
effectiveness trials has been collapsed; but this is still
highly relevant to the discussion here.
In considering the contents of Table 2, and assuming
they represent a logical, coherent, and desirable sequence
of phases, the question arises to what extent the history of
research on alcohol BI has conformed to it. It seems obvi-
ous to the present author that the answer to this question
is “hardly at all.” For example, in the first-ever trial of alco-
hol BI in primary health care in Dundee, Scotland [17],
the investigators were blissfully unaware of the need to
begin by establishing efficacy and plunged directly into a
test of the DRAMS BI package in everyday conditions of
busy general medical practice. Later well-known trials
[18-21] may have included more features of efficacy re-
search, for example, by using artificial methods of screen-
ing and identifying risky drinkers rather than leaving this
to routine practice as in the DRAMS trial [17], but inter-
ventions were still conducted in real-world conditions of
primary care.
A collection of studies that could lay some claim to
being a logical progression of research was the WHO
Collaborative Project on Identification and Management
of Alcohol-related Problems in Primary Health Care
[22]. (The WHO project was divided into four phases of
research over 20 years, but these phases should not be
Table 1 Three levels of experimental assessment
determined by variation in three factors (adapted from
Flay [12])
Level of experimental
assessment
Program
implementation
Availability Acceptance
Efficacy Standardized Optimized Optimized
Treatment effectiveness Efficacious Optimized Variable
Implementation
effectiveness
Efficacious Variable Variable
Table 2 Phases of alcohol problem prevention research
(from Holder et al., 1999 [16])
I. Foundational research: Basic studies to define and determine the
prevalence of specific alcohol-involved problems, establish the
causal factors that yield specific problems or increase the risk of a
problem, and provide foundations for the development of effective
preventive interventions.
II. Developmental studies: Preliminary studies to develop and test new
interventions or to assess the effectiveness of an existing
intervention
III. Efficacy studies: Rigorous studies (of maximised internal validity) of
the intervention under optimal conditions with maximal
implementation (availability or enforcement) and acceptance
(participation or compliance)
IV. Effectiveness studies: Studies of real-world effectiveness of prevent-
ive interventions with purposeful or natural variations.
V. Diffusion studies: Studies of the effects of different levels or types of
implementation or acceptance on effectiveness
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confused with the phases of alcohol problem prevention
research shown in Table 2.) This progression included:
foundational research (see Table 2) in WHO Phase I, the
development of a screening instrument, the AUDIT,
specifically intended for use in primary health care [23];
a number of implementation effectiveness trials in dif-
ferent countries in WHO Phase III [24]; and a diffusion
study in WHO Phase IV [25]. However, WHO Phase II
[26] was again carried out in real-world conditions and
did not show all the essential features of an efficacy trial.
The argument here is that the great majority of trials
of alcohol BI in the literature have not, as Saitz [7] sug-
gests, been efficacy trials, but treatment effectiveness trials.
In Flay’s [12] terms, they were trials that have ensured the
availability of the intervention by delivering a BI to all par-
ticipants in a standard package but have left acceptability
free to vary; to be an efficacy trial, it must be ensured that
the BI has been accepted (complied with, adhered to) by
selecting participants for the study among whom accept-
ance can be assumed, rather than participants encoun-
tered in routine practice among whom it cannot. This
argument will be subjected to more objective scrutiny later
in this article, when the relevant findings of the meta-
analysis by Kaner and colleagues [8] will be described.
To anticipate one of the conclusions of this article,
what are the implications of this argument, if accepted,
for ongoing research on BI? As far as the primary care
setting is concerned, we are, in the popular phrase,
where we are; there is no suggestion here of turning the
clock back to carry out efficacy research. The efficacy of
BI in primary care can be inferred from the fact that it
has emerged with evidence of beneficial effects from a
long succession of systematic reviews and meta-analyses
[27]. It is difficult to believe that this situation could
have arisen without BI being efficacious, although the con-
clusion might have been reached earlier if treatment ef-
fectiveness research had been preceded by efficacy trials.
To implement BI research in the increasing number of
settings in which it is desired (e.g., dentistry, colonoscopy,
needle and syringe exchange programs, pharmacies, a
range of criminal justice and educational settings) and
where there is as yet no evidence base to speak of, there is
an opportunity to conduct studies properly by beginning
with foundational research where necessary, developmen-
tal studies (e.g., to discover the ways in which BI should be
adjusted to the needs and characteristics of the recipients
and the exigencies of the particular settings), and efficacy
trials under carefully controlled conditions of intervention
availability and participant compliance. To do so, rather
than going directly to effectiveness trials, will eventually
save time and money. Unfortunately, there are often pres-
sures from funders and other stakeholders for rapid results
and quick justifications for policies aimed at implementing
BI in as many plausible settings as possible. These political
pressures should be resisted in the interests of real pro-
gress on how to implement alcohol BI to reduce harm.
Flay’s later work
Flay has continued his work in this field of study and in
2005 produced a report with colleagues based on the de-
liberations of a committee established by the Society for
Prevention Research in the United States and charged
with establishing standards for identifying effective pre-
vention programs and policies [28]. This report con-
cluded that an efficacious intervention will have been
tested in at least two rigorous trials that: (i) involved de-
fined samples from defined populations; (ii) used psycho-
metrically sound measures and data collection procedures;
(iii) analyzed their data with rigorous statistical ap-
proaches; (iv) showed consistent positive effects (with-
out serious iatrogenic effects); and (v) reported at least
one significant long-term follow-up.
An effective intervention will not only meet all stan-
dards for efficacious interventions but also will have: (i)
manuals, appropriate training, and technical support
available to allow third parties to adopt and implement
the intervention; (ii) been evaluated under real-world
conditions in studies that include sound measurement at
the level of implementation and engagement of the tar-
get population (in both the intervention and control
conditions); (iii) indicated the practical importance of
the intervention outcome effects; and (iv) clearly dem-
onstrated to whom the intervention findings can be
generalized.
Lastly, an intervention recognized as ready for broad
dissemination will not only meet all standards for effica-
cious and effective interventions but will also provide:
(i) evidence of the ability to go to scale; (ii) clear cost in-
formation; and (iii) monitoring and evaluation tools so
that adopting agencies can monitor or evaluate how
well the intervention works in their settings. All these
and the preceding recommendations from Flay’s later
work are directly relevant to research on alcohol BI.
Analysis of the efficacy-effectiveness dimension in the
2007 Cochrane systematic review
As noted above, the issue of efficacy versus effectiveness
of research in the alcohol BI field was subjected to em-
pirical scrutiny in a highly influential systematic review
and meta-analysis by Kaner and colleagues [8]; this has
already been referred to above in summarizing the ex-
change of views between Saitz [7] and the SIPS investi-
gators [9] following the publication of the primary care
arm of the SIPS trial [5].
A subgroup analysis was undertaken to assess the
impact of brief interventions in efficacy (ideal-world)
and effectiveness (real-world) trials using a coding
scale adapted from the work of Shadish and colleagues
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[29]. Note immediately the assumption here that the
distinction between efficacy and effectiveness forms a
multidimensional domain and can be represented as
continuous variation along a scale. Shadish et al. had
used 10 codes to distinguish between ideal and real-
world trials of psychological therapy in general and
had applied these codes to 60 trials to generate a scale
score for each, which they then related to the trials’ re-
ported effect sizes. The conclusion of this exercise, in-
cidentally, was that “… psychological therapies are
robustly effective across conditions that range from
research-oriented to clinically representative” (p. 522).
The eight coding items that were adapted from the
codes of Shadish and colleagues and were applied to all
21 RCTs included in the Cochrane Review are shown in
Table 3. The four items thought on a priori grounds to
have greater relevance to the effectiveness of alcohol BI
scored 2/0, and the four items with less apparent rele-
vance scored 1/0, giving a range of scores from zero to
12. If an item appeared to be partially clinically representa-
tive on any item, then a midpoint score was given (either
1 or 0.5, as applicable). Similarly, if authors did not report
data relating to a particular item, the midpoint score was
used. Each trial was independently coded by two authors.
If there was disagreement concerning a coding, this was
resolved through discussion in order to gain consensus.
Figure 1 shows the estimated treatment (i.e., interven-
tion) effect of a trial on the ordinate, plotted against its
score on the efficacy-effectiveness dimension on the ab-
scissa (with increasing scores indicating greater effective-
ness.) It will be seen that scores tended toward the right-
hand of the scale; i.e., in the direction of greater scores
towards the effectiveness end of the spectrum, with a
median of 9 and an inter-quartile range of 8–10.5.
Scores ranged from 4.5 [30,31] to 12 [32].
For the purpose of further subgroup analysis, a binary
variable was created with a cut-point at the median, with
those trials to the left of the median in Figure 1 being
classified as efficacy trials, while those to the right were
classified as effectiveness trials, remembering that these
labels are relative because most trials had scores towards
the effectiveness end of the spectrum. Comparing these
two groups, there was no significant difference between
trials classified as effectiveness and efficacy trials in the
effect of brief intervention on the quantity of alcohol
consumed; further, meta-regression showed no signifi-
cant relationship between the estimated treatment effect
and the efficacy score of the trial. Inspection of Figure 1
Table 3 Eight coding items used to form a scale of efficacy-effectiveness (or clinical representativeness) (adapted from
Kaner et al. [8])
Patients and problems Therapeutic flexibility
2 = clinically representative subjects initially present with a typically wide
range of problems via self-referral or invitation for a health check.
1 = clinically representativeness allows professional judgement in how an
intervention is delivered (e.g., freedom to focus on particular issues
according to patient need).
0 = research representative subjects may be paid patients, researcher-
solicited volunteers (e.g., via advertisement) or referrals from specialist
services.
0 = research representativeness would be strict adherence to a prescribed
protocol or script that does not allow for variability in practice.
Practice context Pre-therapy training
2 = clinically representative is a community-based setting in which a
range of clinical services are usually provided to patients.
1 = clinically representative training in intervention procedures occurs
according to typical CPD/CME procedures (e.g., outreach visits, seminars,
one-off training days).
0 = research representative is a setting in which the research function
clearly dominates any clinical one (e.g., clinic at a university or hospital).
0 = research representative training is unusually intensive or requiring of
atypical levels of interest or motivation (e.g., prolonged or intensive
courses, formal qualification).
Practitioners and therapists Intervention support
2 = clinically representative practitioners are practising doctors, nurses,
and qualified therapists who earn their main living by providing health
services in primary care.
1 = clinically representative support occurs within standard practice
resources (e.g., colleague assistance with screening, IT flagging).
0 = research representative practitioners are nonclinicians or clinicians in
training who are contracted to deliver interventions for the purposes of
the study.
0 = research representative support would not typically be available (e.g.,
researcher help to flag notes, extra staff for period of the trial).
Intervention content Intervention monitoring
2 = clinically representative intervention fits with current practice in terms
of timing, content or style (e.g., 5–15 minutes for a GP; 20–30 minutes for
a nurse or initial screening accompanied by a return visit for brief
intervention).
1 = clinically representative monitoring of intervention delivery does not
interfere with practitioners’ behaviour or their relationship with patients.
0 = research representative treatment would not normally occur in
routine practice (e.g., unusually long consultations).
0 = research representative monitoring would be direct observation of
therapist behaviour or ongoing/immediate feedback to practitioners after
each session.
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confirms that there is little if any relationship between a
trial’s score on the efficacy-effectiveness dimension and
its effect size. The authors do concede the possibility
that this lack of relationship may indicate insensitivity in
the classification tool. Nevertheless, they conclude:
“In the field of brief alcohol intervention, there has
been a growing view that most of the trials to date
have been tightly controlled efficacy studies and not
particularly representative of routine clinical practice
(Babor et al., 2006) [33]. …..within the context of
trial-based evaluation, we feel that the current body of
brief alcohol intervention research is applicable to
clinical practice. Previous trials have fallen on a
continuum from efficacy to effectiveness trials, and
the lack of significant difference in outcomes on this
dimension suggests that this body of work can inform
routine practice” (p. 19).
In addition to the reference to the work of Babor and
colleagues [33] in the quotation above, if it had been
available to them at the time, the authors of the Cochrane
Review could have cited the letter by Saitz in the British
Medical Journal [7] commenting on the SIPS findings.
Thus, an implication of the results of the subgroup ana-
lysis summarized above is that Saitz is mistaken in be-
lieving that the majority of BI trials in the literature are
efficacy trials or that effectiveness trials tend to have
weaker effects on treatment outcome than efficacy trials
(or, at least, those tending more towards the efficacy
end of the spectrum). Hence, if the subgroup analysis in
question is valid, the null findings of the trials described
at the outset of this article cannot be attributed to the
difficulty in translating effects of BI seen in efficacy tri-
als to effectiveness trials.
Before this conclusion and its implications are fully ac-
cepted, however, it must be recognized that the sub-
group analysis in question can be criticized on technical
grounds. First, although it was reported that trials were
independently coded by two authors, there was no
mention of pilot work to establish the reliability of the
codings, and no measure of agreement between coders
was reported. Perhaps more damagingly, no psycho-
metrics were carried out on the efficacy-effectiveness
scale; e.g., principal components analysis to test for
unidimensionality and then deletion of coding items
that lowered Cronbach’s alpha. Lastly, there were no
comparisons between the efficacy and effectiveness
trial groups on effect sizes for individual scale items.
This possibility was recognized by the authors when
they wrote: “It is possible that the treatment effect may
be related to some of the individual factors, which were
combined in the efficacy score. However, we did not in-
vestigate this as it would have been a post hoc analysis,
not specified in the protocol” [8] (p. 17).
As this suggests, an analysis of this kind could be
planned for inclusion in any future meta-analysis of BI
RCTs. More generally, the subgroup analysis could be
repeated in a future meta-analysis without the flaws iden-
tified above. Whether this would make any difference to
the general conclusion reached regarding the essential ef-
fectiveness of most trials in the literature is an interesting
empirical question.
One last point should be made about the subgroup
analysis in the Cochrane Review. In discussing the inter-
pretation of their coding scheme and scale, Shadish
et al. [29] specifically reject the idea that the degree of
clinical representativeness of trials they aim to measure
can be equated with efficacy-effectiveness based on in-
ternal versus external validity. To do so, they say, results
in an oversimplification because, in classic discussions
of internal-external validity [34,35], the crucial meth-
odological features for high internal validity are random
assignment and the minimization of attrition. It is
clearly possible for a trial that is clinically representative
to meet these two criteria and thus to be both clinically
representative and internally valid. This persuasive ar-
gument suggests that the dimension analyzed by Kaner
and colleagues in the 2007 Cochrane Review [8] was
clinical representativeness, not efficacy-effectiveness
based on relative degrees of internal and external validity.
Other relevant scales
Before concluding this review of the efficacy-effectiveness
dimension, it may be useful to note the publication of
two other scales with relevance to the issue. In the first,
Gartlehner and colleagues [36] developed and tested a
simple instrument based on seven criteria of study de-
sign to distinguish effectiveness from efficacy trials.
Figure 1 Estimated treatment effect versus effectiveness/
efficacy score. The lines show the predicted metaregression line
and its 95%CI. (from Kaner et al. [8,24]). NB. Increasing scores on the
abscissa indicate greater effectiveness.
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These authors began by noting that no validated defin-
ition of ‘effectiveness study’ exists. They carried out a
search for existing scales to measure the efficacy-
effectiveness dimension but found none. (They obvi-
ously missed the scale developed by Kaner and col-
leagues [8] and noted above, perhaps because it was
buried in a longer Cochrane Review; this suggests the
need to make the issue of efficacy-effectiveness or the
clinical representativeness of trials the topic of separate
publications.) It should be stressed, however, that the
efficacy-effectiveness scale developed in this project,
based as it was on research design and influenced
largely by a conventional understanding of internal and
external validity, was very different from the scale used
by Kaner and colleagues [8], suggesting again that the lat-
ter would be better termed “clinical representativeness.”
The second novel scale was developed by Thorpe and
colleagues [37] and was intended to reflect the explanatory-
pragmatic dimension. However, these authors’ under-
standing of an explanatory trial differed from that of the
originators of this term; i.e., as describing trials that
were designed to test causal hypotheses regarding the
way an intervention exerts its effect [10], and was based
rather on trials that aimed to provide an answer to the
question, “Can this intervention work under ideal con-
ditions?” (as opposed to pragmatic trials, which tried to
answer the question, “Does this intervention work
under usual conditions?”). This unhelpful change in ter-
minology illustrates again how easily confusion can be
introduced into this field of study by careless use of
terms. Nevertheless, this scale, which differs again from
the two considered above [8,37], may be useful to re-
searchers. Indeed, in future meta-analyses of alcohol BI
trials, two or even all three of the scales considered
here, measuring as they do somewhat different aspects
of ideal-world versus real-world trials, could be used
and relationships between them explored.
Conclusions
The following are summaries of conclusions in the pre-
ceding text:
1. There is considerable confusion and inconsistency
in the literature regarding such terms as efficacy
trial, effectiveness trial, explanatory trial, pragmatic
trial, and clinical representativeness. In the future,
these terms should be clearly defined and carefully
used.
2. It is a mistake to go straight to effectiveness trials
for new forms of alcohol BI intended for different
populations in different settings where the evidence
base is thin or nonexistent. The development and
testing of new applications of BI should begin with
foundational research and developmental studies,
followed by efficacy trials, before large-scale effect-
iveness trials are mounted. Political pressures for
quick results from premature effectiveness trials
should be resisted.
3. Clear criteria are available in the literature to guide
progress in movement from efficacy research,
through effectiveness research, to dissemination in
practice.
4. To properly interpret the findings of effectiveness
studies, especially null findings, it is necessary to
ensure that interventions are delivered as intended
and as found efficacious or effective in previous
research.
5. In future meta-analyses of alcohol BI trials, more
attention should be paid to the development and
application of a scale to measure efficacy-effectiveness
or clinical representativeness, including: theory-based
scale construction; inter-rater reliability testing and
reporting; psychometric scale refinement; and
publication as a topic of interest in its own right.
6. In relation to the three disappointing findings with
which this article began:
a. The null findings of the van Beurden et al. trial
[2] are not relevant to the issue of translating
efficacy into treatment effectiveness because they
represent a failure of implementation
effectiveness. They reinforce strongly what is
already known – that it is extremely difficult to
get health professionals to deliver alcohol BI.
b. The null findings of the SIPS trial [5] cannot be
firmly attributed to a failure to translate effects
from efficacy trials to real-world practice because
it is possible that the majority of trials included in
meta-analyses on which the evidence for the
beneficial effects of alcohol BI is based tended to
be effectiveness trials rather than efficacy trials
(although the validity of this conclusion should
be more rigorously tested in future meta-analyses
of alcohol BI).
c. A leading hypothesis to explain the null findings
of the SIPS [5] and PRE-EMPT [3] trials is that they
are due to lack of fidelity in the implementation
of BI in large, complex, cluster randomized
trials.
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